Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer

Background TAS-102 is a nucleoside antitumor agent consisting of trifluridine (FTD) and tipiracil hydrochloride (TPI). We investigated the recommended dose (RD) of TAS-102 plus irinotecan for metastatic colorectal cancer refractory to 5-fluorouracil (5-FU) and oxaliplatin. Methods This study was use...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Doi, Toshihiko, Yoshino, Takayuki, Fuse, Nozomu, Boku, Narikazu, Yamazaki, Kentaro, Koizumi, Wasaburo, Shimada, Ken, Takinishi, Yasutaka, Ohtsu, Atsushi
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2015
Assuntos:
Phase I Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4768213/
https://ncbi.nlm.nih.gov/pubmed/26163340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0271-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados